Skip to main content

Results

Select by year

Select period of competence

9M 2024 Results Presentation
Listen audio
Download transcript
Download press release
Download presentation
Q2 2024 Results Presentation
Listen audio
Download transcript
Download press release
Download presentation
Q1 2024 Results Presentation
Listen audio
Download transcript
Download press release
Download presentation
FY 2023 Results Presentation
Listen audio
Download transcript
Download press release
Download presentation
9M 2023 Results Presentation

Third Quarter results confirm guidance for Fiscal Year 2023

Listen audio
Download presentation
Download press release
Download transcript
H1 2023 Results Presentation

Revenues at constant perimeter of consolidation and ex-Covid up 5% at CER in Q2. FY 2023 Guidance Confirmed

Listen audio
Download presentation
Download press release
Q1 2023 Results Presentation

Q1’23 REVENUES CONFIRM GUIDANCE FOR FISCAL YEAR 2023

Listen audio
Download presentation
Download press release
Download transcript
FY 2022 Results Presentation

REVENUE GROWTH, STRONG PROFITABILITY AND ROBUST CASH FLOW GENERATION IN 2022. PROPOSED ORDINARY DIVIDEND OF €1.10 PER SHARE

Listen audio
Download presentation
Download press release
Download transcript
9M 2022 Results Presentation

Revenue growth and strong profitability in the first 9 months of 2022 - Full year 2022 Guidance revised upwards

Listen audio
Download presentation
Download press release
Download transcript
H1 2022 Results Presentation

Strong revenues growth in the First Half of 2022 - Full Year 2022 Guidance on both Revenues and Profitability revised upwards

Listen audio
Download presentation
Download press release
Download transcript
Q1 2022 Results Presentation

Strong growth in revenues and cash flow generation in Q1 2022 - Full Year 2022 Guidance revised upwards

Listen audio
Download presentation
Download press release
Download transcript
FY 2021 Results Presentation

DiaSorin business momentum and the Luminex acquisition drive up revenues, net result and cash flow generation in 2021

Listen audio
Download presentation
Download press release
Download transcript
9M 2021 Results Presentation

DiaSorin business momentum and the Luminex acquisition drive Revenues and Profitability up in the first 9 months of 2021

Listen audio
Download presentation
Download press release
Download transcript
H1 2021 Results Presentation

DiaSorin: Revenues and Profitability continue upward momentum in the First Half of 2021, with Guidance raised following the acquisition of Luminex

Listen audio
Download presentation
Download press release
Download transcript
Q1 2021 Results Presentation

DiaSorin: significant growth in Revenues and Profitability in the first quarter 2021

Listen audio
Download presentation
Download press release
Download transcript
FY 2020 Results Presentation

Revenues, Profitability and Cash Flow Generation hit record highs in 2020

Listen audio
Download presentation
Download press release
Download transcript
9M 2020 Results Presentation

North America growth drives up revenues and profitability in the first 9 months of 2020

Listen audio
Download presentation
Download press release
Download transcript
H1 2020 Results Presentation

North America business growth drives Group revenues and profitability in H1 2020

Listen audio
Download presentation
Download press release
Download transcript
Q1 2020 Results Presentation

DiaSorin Group reports revenue growth and confirmed profitability in the first quarter 2020 despite the impact of the pandemic

Listen audio
Download presentation
Download press release
Download transcript
FY 2019 Results Presentation

DiaSorin - Cash flow generation and net profit hit record highs in 2019

Listen audio
Download presentation
Download press release
Download transcript
9M 2019 Results Presentation

Record free cash flow generation along with growth in revenues and profitability for DiaSorin in the first 9 months of 2019

Listen audio
Download presentation
Download press release
Download transcript
H1 2019 Results Presentation

DiaSorin Board of Directors approves first half 2019 results. Growth in revenues and profitability.

Listen audio
Download presentation
Download press release
Download transcript
Q1 2019 Results Presentation

DiaSorin Group reports growth in profitability and strong free cash flow generation in the first quarter 2019

Listen audio
Download presentation
Download press release
Download transcript
FY 2018 Results Presentation

Growth in revenues, profitability and net profit in 2018

Listen audio
Download presentation
Download press release
Download transcript
9M 2018 Results Presentation

DiaSorin Group reports growth in revenues and net profit in the first nine months of 2018

Listen audio
Download presentation
Download press release
Download transcript
H1 2018 Results Presentation

The Board of Directors approves the results for the first half of 2018

Listen audio
Download presentation
Download press release
Download transcript
Q1 2018 Results Presentation

The DiaSorin Group reports growth in revenues and profitability in the first quarter 2018

Listen audio
Download presentation
Download press release
Download transcript
FY 2017 Results Presentation

DiaSorin: FY 2017 Results

Listen audio
Download presentation
Download press release
Download transcript
FY 2016 Results Presentation

The Board of Directors approves the results for FY'16

Listen audio
Download presentation
Download press release
Download transcript
FY 2015 Results Presentation

The Board of Directors approves the results for FY'15

Listen audio
Download presentation
Download press release
Download transcript
FY 2014 Results Presentation

The Board of Directors approves the results for FY'14

Listen audio
Download presentation
Download press release
Download transcript